MidMarketNow
Get the Weekly

CureVac

—

SectorsHealthcare1
Regions—
Last activity

Activity, last 12 months

CureVac — events per month, last 12 months
CureVac — events per month, last 12 months
MonthEvents
August 20250
September 20250
October 20250
November 20250
December 20251
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260

Deal history

  1. BioNTech closes CureVac deal to deepen mRNA stack

    BioNTech has completed its acquisition of CureVac after 86.75% of shares were tendered, consolidating two German mRNA pioneers. The all-stock transaction sharpens BioNTech’s oncology focus and clears a long-running IP overhang.

We use privacy-respecting product analytics to understand how readers use MidMarketNow and improve it. No personal data (email, IP) is sent. See our privacy policy.